Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1).
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1).
复制标题
DOI：
10.1097/jto.0b013e318292be18
复制
发表时间：
2013-06
期刊：
影响因子：
--
通讯作者：
Schalper KA
中科院分区：
文献类型：
--
作者：
Velcheti V;Rimm DL;Schalper KA
程序性死亡-1(PD-1)是一种存在于T细胞和巨噬细胞上的共抑制诱导受体。程序性死亡配体-1(PD-L1)增加的肿瘤细胞被认为通过激活PD-1/PD-L1途径和抑制效应器免疫反应来逃避免疫。最近针对PD-1/PD-L1轴的策略在包括肺癌在内的几种肿瘤类型的患者中显示出良好的结果。初步数据表明，PD-L1蛋白的表达可能预示着对此类治疗的反应。肺的肉瘤样癌包括少见的亚型低分化非小细胞肺癌(NSCLC)，具有高度恶性和侵袭性。这些肿瘤的生物学特性知之甚少，通常表现为局部炎症和淋巴细胞浸润增加。在这里，我们报告了来自两个大型回顾性肺癌队列的13个干细胞中PD-L1的表达。应用自动定量免疫荧光(AqIF/AQA®)和针对PD-L1胞外区的小鼠单抗，我们发现13例SCs患者中有9例PD-L1阳性(69.2%)，且其水平高于常规非小细胞肺癌。这些结果为肺干细胞靶向免疫治疗的潜在应用提供了理论依据。
Programmed death-1 (PD-1) is a co-inhibitory inducible receptor present on T-cells and macrophages. Tumor cells with increased programmed death ligand-1 (PD-L1) are believed to escape immunity through activation of PD-1/PD-L1 pathway and suppression of effector immune responses. Recent strategies targeting the PD-1/PD-L1 axis have shown promising results in patients with several tumors types, including lung carcinomas. Preliminary data suggests that PD-L1 protein expression might predictive response to such therapies. Sarcomatoid carcinomas (SCs) of the lung include rare subtypes of poorly differentiated non-small cell lung carcinomas (NSCLC) of high grade and aggressive behavior. The biology of these neoplasms is poorly understood and they frequently show increased local inflammatory and lymphocytic infiltration. Here, we report the expression of PD-L1 in 13 SCs from two large retrospective lung cancer cohorts. Using automated quantitative immunofloresence (aqIF/AQUA®) and a mouse monoclonal antibody directed against the extra-cellular domain of PD-L1, we show that 9 of 13 (69.2%) patients with SCs are positive for PD-L1 and their levels are higher than in conventional NSCLC. These results provide rationale for the potential use of targeted immunetherapy in lung SCs.